
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Study Phase : Phase III
Sponsor : Specialised Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Treeway Licensing Deal with Specialised Therapeutics
Details : Under the licensing agreement, ST will be responsible for all marketing, regulatory and distribution activities of TW001, a unique oral formulation of edaravone which works by reducing the oxidative damage associated with neuron death in ALS, in Australi...
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
August 28, 2023
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Highest Development Status : Phase III
Sponsor : Specialised Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement

ASURE: Alzheimer Study Using oRal Edaravone
Details : TW001 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 12, 2022

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Study Phase : Phase III
Recipient : Ferrer Internacional
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Ferrer Signs License Agreement To Develop An Oral Formulation Treatment For Patients With ALS
Details : FNP122 is an oral formulation of edaravone, a compound that prevents oxidative stress on a cellular level. Therefore, reducing oxidative stress can delay the progression of ALS.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
October 20, 2021
Lead Product(s) : Edaravone
Therapeutic Area : Neurology
Highest Development Status : Phase III
Recipient : Ferrer Internacional
Deal Size : Undisclosed
Deal Type : Licensing Agreement
